ARPA-H launches $160 million THRIVE program to fund seven labs developing custom gene-editing therapies for rare diseases

ARPA-H, the U.S. Advanced Research Projects Agency for Health, announced a new initiative called THRIVE with up to $160 million in funding.

The program will support seven research teams over five years to develop custom gene‑editing approaches aimed at treating a range of rare diseases affecting different organ systems.

Each team is required to begin clinical trials within three years of the award, though some may start earlier, reflecting the agency’s goal of accelerating therapeutic development.

The effort follows a delay caused by a change in administration and represents a significant public‑sector investment in precision gene‑editing technologies.